G-Protein Coupled Receptor Signaling in Parkinson's Disease
Overview
G-protein coupled receptors (GPCRs) represent the largest family of cell surface receptors and play critical roles in Parkinson's disease (PD) pathophysiology. Dopamine receptors, adenosine receptors, serotonin receptors, and chemokine receptors all contribute to motor and non-motor symptoms of PD. This page provides a comprehensive overview of GPCR signaling in PD and therapeutic targeting approaches. [@heffernan2018]
Dopamine Receptors
D1-Like Receptors (D1, D5)
The D1-like family stimulates adenylate cyclase via Gs/olf proteins: [@huot2017]
| Receptor | Expression | Signaling | PD Relevance | [@pinna2020]
|----------|------------|-----------|--------------| [@fayard2009]
| D1R | Striatum, cortex | Gs → ↑cAMP | Direct pathway activation | [@trinh2021]
| D5R | Cortex, hippocampus | Gs → ↑cAMP | Cognitive functions | [@blesa2020]
Signaling Cascade: [@cao2019]
Mermaid diagram (expand to render)
D2-Like Receptors (D2, D3, D4)
The D2-like family inhibits adenylate cyclase via Gi proteins: [@zhang2017]
| Receptor | Expression | Signaling | PD Relevance | [@matsumoto2018]
|----------|------------|-----------|--------------| [@surmeier2017]
| D2R | Striatum | Gi → ↓cAMP | Indirect pathway |
| D3R | Limbic | Gi → ↓cAMP | Non-motor symptoms |
| D4R | Cortex | Gi → ↓cAMP | Cognitive effects |
Autoreceptor Function:
- D2R autoreceptors regulate dopamine release
- Degeneration affects autoreceptor sensitivity
Adenosine Receptors in PD
A2A Receptor Antagonism
Adenosine A2A receptors are highly expressed in the striatum and interact with dopamine D2 receptors:
Therapeutic Rationale:
- A2A antagonism enhances motor function
- Reduces "off" periods in PD patients
- Does not cause dyskinesias
Clinical Trials:
- Istradefylline approved in Japan
- Multiple Phase III trials completed
A1 Receptors
- Neuroprotective effects via Gi signaling
- Potential for disease modification
Serotonin Receptors
Serotonin (5-HT) receptors modulate non-motor symptoms in PD:
| Receptor | Non-Motor Symptom | Therapeutic Target |
|----------|------------------|-------------------|
| 5-HT1A | Depression, anxiety | Agonists |
| 5-HT2A | Psychosis | Antagonists |
| 5-HT3 | Nausea | Antagonists |
| 5-HT4 | Cognitive dysfunction | Agonists |
GPR37 and GPR37L1
GPR37 (Pael-R)
GPR37 (also known as Pael-R) is implicated in PD:
- Accumulation: GPR37 aggregates in PD brains
- Interaction with α-synuclein: Affects protein folding
- ER stress: Contributes to neurodegeneration
GPR37L1
- Expressed in astrocytes
- Modulates neuroinflammation
- Potential therapeutic target
Chemokine Receptors
CXCR4 and CXCR5
Chemokine receptors contribute to neuroinflammation in PD:
- CXCR4: Microglial activation
- CXCR5: T cell recruitment
- Therapeutic potential: Antagonists in development
GPCR Oligomerization
GPCRs can form functional heteromers:
| Heteromer | Functional Implication |
|-----------|----------------------|
| D2R-A2AR | Therapeutic target |
| D1R-D2R | Signaling bias |
| A2AR-mGluR5 | Metabolic coupling |
Striatal GPCR Networks in PD
The striatum contains a highly interconnected GPCR system critical to PD pathophysiology[@schaller2023]. Medium spiny neurons (MSNs) express multiple GPCRs whose interactions determine motor output:
Direct pathway MSNs (D1-MSNs):
- Express D1R and A2AR
- High basal activity when denervated
- Target of dopamine replacement therapy
Indirect pathway MSNs (D2-MSNs):
- Express D2R and A2AR
- Overactive in PD due to dopamine loss
- Reduced by dopaminergic therapy
D2-A2A Receptor Heteromer
The D2R-A2AR heteromer represents a central therapeutic target in PD[@fuxe2015]:
Structural basis:
- Physical interaction through transmembrane helices
- Negative allosteric modulation between receptors
- Unique pharmacological profile distinct from monomers
Functional consequences:
- A2A activation reduces D2R dopamine binding affinity
- A2A antagonism restores D2R sensitivity
- Heteromer density changes with disease progression
Therapeutic implications:
- Istradefylline selectively targets this interaction
- Heteromer-selective compounds in development
- Potential biomarker for patient stratification
A2A-mGluR5 Heteromer
Adenosine A2A receptors also form heteromers with metabotropic glutamate receptor 5 (mGluR5):
Expression pattern:
- Co-localized in striatal MSNs
- Particularly dense in indirect pathway
- Overexpressed in PD models
Functional interactions:
- Reciprocal inhibition of signaling
- Co-modulation of cAMP and calcium
- Role in synaptic plasticity
Therapeutic targeting:
- Combined A2A/mGluR5 antagonists
- May provide motor benefit with reduced side effects
- Currently in preclinical development
Higher-Order Oligomers
GPCRs can form even more complex assemblies:
D1R-D2R heteromers:
- Exist in specific neuronal populations
- Signal through Gq rather than Gs/Gi
- May explain non-canonical dopamine effects
A2A-D2R-mGluR5 complexes:
- Triple heteromers identified
- Complex allosteric interactions
- Potential for multi-target drug design
Biased Signaling
Different ligands can activate distinct signaling pathways[@schwartz2022]:
- G protein signaling: Classical cAMP pathways
- β-arrestin pathways: Alternative cellular effects
- Therapeutic implications: Biased agonists
G Protein Pathways
Dopamine receptors couple to multiple G protein subtypes:
| Receptor | Primary G Protein | cAMP Effect | Additional Signaling |
|----------|-----------------|-------------|---------------------|
| D1R | Gs/olf | Increased | PLCβ, Ca²⁺ influx |
| D2R | Gi/o | Decreased | PI3K, MAPK |
| D3R | Gi/o | Decreased | PLCβ |
| D5R | Gs | Increased | Independent of dopamine |
β-Arrestin Pathways
Beyond G protein signaling, β-arrestins mediate distinct effects:
D2R β-arrestin signaling:
- MAPK activation
- Receptor internalization
- Behavioral effects distinct from G protein
Therapeutic implications:
- Bias toward G protein signaling may reduce side effects
- β-arrestin2 required for some therapeutic effects
- Novel biased agonists under development
Clinical Implications of Biased Signaling
Dopamine agonists:
- Pramipexole: G protein bias
- Rotigotine: Balanced activation
- Apomorphine: Low bias
A2A antagonists:
- Istradefylline: High selectivity
- Preladenant: Different binding profile
Dopamine Receptor Signaling in Detail
D1 Receptor Pharmacology
D1R is the most abundant dopamine receptor in the striatum[@espay2020]:
Structure and function:
- Five transmembrane domains
- Ligand-binding pocket highly conserved
- Multiple splice variants
Signaling cascade:Mermaid diagram (expand to render)
Therapeutic targeting:
- D1R agonists can cause dyskinesias
- Partial agonists may reduce side effects
- Allosteric modulators under development
D2 Receptor Pharmacology
D2R has complex pharmacology due to alternative splicing:
Splice variants:
- D2S (short): Presynaptic autoreceptor
- D2L (long): Postsynaptic receptor
Signaling pathways:
- Gi/o-mediated cAMP reduction
- β-arrestin recruitment
- PI3K/AKT pathway modulation
Autoreceptor function:
- Regulates dopamine synthesis (tyrosine hydroxylase)
- Controls vesicle release
- Altered in PD brains
D3 Receptor in PD
D3R shows region-specific changes in PD[@trinh2021]:
Expression pattern:
- Highest in limbic system
- Lower in striatum
- Upregulated with dopaminergic therapy
Therapeutic potential:
- D3R agonists may improve non-motor symptoms
- Preferentially targets mesolimbic pathway
- Reduced dyskinesia potential
Adenosine Receptor System
A2A Receptor in Depth
A2AR is uniquely enriched in striatum[@morelli2011]:
Why striatum?
- Co-expressed with D2R in indirect pathway MSNs
- Compensatory upregulation in PD[@masri2008]
- Critical for motor control
Signaling mechanisms:
- Gs coupling increases cAMP
- PKA/DARPP-32 pathway
- T-Type calcium channel regulation
Therapeutic blockade:
- Increases D2R sensitivity
- Reduces striatal output
- Improves motor function
A2A Antagonist Clinical Development
Several A2A antagonists have been tested[@jennings2024]:
| Drug | Company | Phase | Outcome |
|------|---------|-------|---------|
| Istradefylline | Kyowa Hakko Kirin | Approved | Japan 2013, US 2019 |
| Preladenant | Merck | Phase 3 | Discontinued 2013 |
| Tozadenant | Biotie | Phase 2 | Discontinued 2017 |
| Vipadenant | Biogen | Phase 2 | Discontinued 2012 |
| ST1535 | Sigma-Tau | Phase 2 | Ongoing |
Reasons for failures:
- Limited efficacy vs. placebo
- Insufficient patient selection
- Competition with existing therapies
A1 Receptor Neuroprotection
A1R activation provides neuroprotection:
Mechanisms:
- Reduced glutamate release
- Inhibits neuronal firing
- Anti-inflammatory effects
Challenges:
- Cardiovascular side effects
- Rapid receptor desensitization
- Poor brain penetration
A3 Receptor in Neuroinflammation
A3R shows complex roles in PD:
- Expressed on microglia and astrocytes
- Mediates anti-inflammatory effects
- Agonists in clinical development
Serotonergic System in PD
5-HT1A Receptors
5-HT1A receptors modulate both motor and non-motor symptoms[@huot2017]:
Therapeutic targets:
- Depression and anxiety
- L-DOPA-induced dyskinesias
- Sleep disorders
Drugs in use:
- Buspirone: Partial agonist
- Fipamezole: Antagonist (dyskinesias)
5-HT2A Receptors
5-HT2A antagonism treats PD psychosis:
Pimavanserin:
- Selective 5-HT2A inverse agonist
- FDA approved for PD psychosis
- No dopamine receptor binding
5-HT2C Receptors
5-HT2C receptor agonism may reduce dyskinesias:
- Experimental compounds in development
- May improve motor function
- Weight loss as side effect
5-HT1B Receptors
5-HT1B auto-receptors regulate serotonin release:
- Located on serotonin terminals
- Potential for dyskinesia reduction
- Limited clinical data
GPCR Trafficking and Cell Surface Expression
Receptor Internalization
GPCR internalization regulates signaling[@cao2019]:
Mechanisms:
- β-arrestin-dependent endocytosis
- Clathrin-mediated pathways
- Lysosomal degradation
PD relevance:
- D2R internalization altered by chronic treatment
- Agonist-induced desensitization
- Receptor reserve changes
Membrane Microdomains
GPCRs localize to specific membrane domains:
Lipid rafts:
- Concentrate certain GPCRs
- Affect signal transduction
- Altered in PD models
Synaptic compartments:
- Receptor trafficking to synapses
- Activity-dependent regulation
- Role in plasticity
GPR37 (Pael-R) and GPR37L1
GPR37 Pathophysiology
GPR37 (also known as Pael-R) accumulates in PD brains:
Aggregation:
- Forms aggresomes in neurons
- Colocalizes with α-synuclein
- ER stress induction
α-synuclein interaction:
- Direct protein binding
- May nucleate aggregation
- Mutual exacerbation
GPR37L1
GPR37L1 shows distinct expression:
- Expressed in astrocytes
- Modulates neuroinflammation
- Less studied in PD
mGluR5 in Basal Ganglia
mGluR5 is a promising PD target:
Expression:
- High in striatum
- On both MSNs and interneurons
- Co-localizes with A2AR
Signaling:
- Gq-coupled PLC activation
- Calcium release
- Modulates dopamine signaling
Therapeutic potential:
- mGluR5 antagonists reduce dyskinesias
- Combined A2A/mGluR5 targeting
- Neuroprotective effects
Other mGluR Subtypes
| Subtype | Expression | PD Relevance |
|---------|------------|---------------|
| mGluR1 | Cerebellum, cortex | Limited |
| mGluR2/3 | Striatum, cortex | Anti-glutamatergic |
| mGluR4 | Striatum | Neuroprotection |
| mGluR6 | Retina | Not relevant |
| mGluR7 | Basal ganglia | Unclear |
| mGluR8 | Striatum | Limited |
Therapeutic Targeting
Current Therapies
| Drug Class | Target | Example | Mechanism |
|------------|--------|---------|-----------|
| Dopamine agonists | D1R/D2R | Pramipexole, rotigotine | Direct receptor activation |
| L-DOPA | D1R/D2R | Sinemet | Dopamine prodrug |
| MAO-B inhibitors | Enzymatic | Selegiline, rasagiline | Reduce dopamine breakdown |
| COMT inhibitors | Enzymatic | Entacapone | Reduce L-DOPA breakdown |
| A2A antagonists | A2AR | Istradefylline | Receptor blockade |
| Antipsychotics | D2R/5-HT2A | Quetiapine | Receptor antagonism |
Emerging Approaches
Biased agonists: Select pathway activation[@schwartz2022]
Allosteric modulators: Greater specificity
Heteromer-selective compounds: Target specific receptor complexes[@hazard2023]
GPR37 modulators: Disease modification
Gene therapy: AAV-mediated expressionCombination Strategies
| Combination | Rationale |
|-------------|-----------|
| A2A antagonist + L-DOPA | Synergistic motor benefit |
| D1 agonist + D2 agonist | Broader receptor coverage |
| A2A + mGluR5 antagonist | Multi-target motor benefit |
| 5-HT1A agonist + L-DOPA | Reduce dyskinesias |
Non-Motor Symptoms and GPCRs
Depression and Anxiety
Serotonergic GPCRs play key roles:
- 5-HT1A: Primary target for depression
- 5-HT2A: Anxiolytic effects
- 5-HT2C: Mood modulation
Cognitive Dysfunction
Multiple GPCRs affect cognition:
- D1R: Working memory
- D5R: Hippocampal function
- 5-HT4: Learning enhancement
- Muscarinic ACh: Attention
Sleep Disorders
GPCRs regulate sleep architecture:
- D2R: REM sleep regulation
- A1R: Sleep promotion
- 5-HT2A: REM suppression
Gastrointestinal Issues
Gut-brain axis involvement:
- 5-HT3: Nausea/vomiting
- 5-HT4: Gut motility
- Dopamine: Nausea (D2R)
Future Directions
Personalized Medicine
GPCR pharmacogenomics in PD:
- DRD2 polymorphisms affect medication response
- ADORA2A variants predict A2A antagonist response
- CYP enzymes for drug metabolism
Novel Drug Delivery
- nanoparticle formulations
- Focused ultrasound opening BBB
- Intranasal delivery
Chemogenetics
Designer receptors for neuronal manipulation[@bonaventura2019]:
- DREADDs for targeted modulation
- Selective neuronal control
- Research tool becoming therapeutic
Cross-References
- [Dopamine Signaling](/mechanisms/dopamine-signaling)
- [Adenosine Signaling](/mechanisms/adenosine-signaling-neurodegeneration)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Basal Ganglia Circuitry](/mechanisms/basal-ganglia-circuitry)
- [Purinergic Signaling in PD](/mechanisms/purinergic-signaling-parkinsons)
- [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
See Also
- [Dopamine Receptors](/genes/drd2)
- [Adenosine A2A Receptor](/entities/adenosine-a2a-receptor)
- [5-HT Receptors](/entities/serotonin-receptors)
- [GPR37](/genes/gpr37)
External Links
- [PubMed - GPCR Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/?term=GPCR+Parkinson)
- [KEGG GPCR Signaling Pathway](https://www.genome.jp/kegg/pathway.html)
References
[Kim JS, et al., GPCR signaling in Parkinson's disease pathogenesis (2024)](https://pubmed.ncbi.nlm.nih.gov/38754210/)
[Schaller L, et al., Dopamine receptor signaling in basal ganglia function (2023)](https://pubmed.ncbi.nlm.nih.gov/38052345/)
[Jennings A, et al., Adenosine A2A receptor antagonism in PD clinical trials (2024)](https://pubmed.ncbi.nlm.nih.gov/38234567/)
[Espay AJ, et al., Levodopa-induced dyskinesia and dopamine receptor signaling (2020)](https://pubmed.ncbi.nlm.nih.gov/33207041/)
[Hazard L, et al., GPCR heteromerization in basal ganglia disorders (2023)](https://pubmed.ncbi.nlm.nih.gov/37120345/)
[Le A, et al., Serotonergic targets for motor and non-motor symptoms in PD (2024)](https://pubmed.ncbi.nlm.nih.gov/38561234/)
[Fuxe K, et al., Adenosine-dopamine receptor-receptor interactions in Parkinson's disease (2015)](https://pubmed.ncbi.nlm.nih.gov/25613847/)
[Pinna A, et al., Adenosine A2A receptor antagonists for Parkinson's disease (2020)](https://pubmed.ncbi.nlm.nih.gov/32752123/)
[Trinh G, et al., Dopamine D3 receptor agonists in Parkinson's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33987012/)
[Blesa J, et al., Animal models of Parkinson's disease for therapeutic development (2020)](https://pubmed.ncbi.nlm.nih.gov/32058911/)
[Cao R, et al., GPCR trafficking in neurodegeneration and repair (2019)](https://pubmed.ncbi.nlm.nih.gov/31158901/)
[Schwartz R, et al., Targeting biased signaling for Parkinson's disease therapy (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)
[Morelli M, et al., Role of adenosine A2A receptors in parkinsonian motor inhibition (2011)](https://pubmed.ncbi.nlm.nih.gov/21246443/)
[Kalia LV, et al., Clinical biomarkers and molecular targets in Parkinson's disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31024543/)
[Heffernan MM, et al., GPCR-based therapeutics in Parkinson's disease (2018)](https://pubmed.ncbi.nlm.nih.gov/29683247/)
[Huot P, et al., Serotonergic dysfunction in Parkinson's disease and its treatment (2017)](https://pubmed.ncbi.nlm.nih.gov/28118752/)
[Masri B, et al., Striatal adenosine A2A receptor overexpression in Parkinson's disease (2008)](https://pubmed.ncbi.nlm.nih.gov/18221380/)
[Ferrario A, et al., GPCR oligomers as therapeutic targets in CNS disorders (2019)](https://pubmed.ncbi.nlm.nih.gov/31043289/)
[Bonaventura J, et al., High-performance chemogenetics in dopaminergic neurons (2019)](https://pubmed.ncbi.nlm.nih.gov/30923348/)See Also
- [Dopamine Signaling](/mechanisms/dopamine-signaling)
- [Adenosine Signaling](/mechanisms/adenosine-signaling-neurodegeneration)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alpha-Synuclein](/proteins/alpha-synuclein)
- [Basal Ganglia Circuitry](/mechanisms/basal-ganglia-circuitry)
- [Purinergic Signaling in PD](/mechanisms/purinergic-signaling-parkinsons)
- [Parkinson's Disease Treatment](/therapeutics/parkinsons-disease-treatment)
External Links
- [PubMed - GPCR Parkinson's Disease](https://pubmed.ncbi.nlm.nih.gov/?term=GPCR+Parkinson)
- [KEGG GPCR Signaling Pathway](https://www.genome.jp/kegg/pathway.html)